TGA grants provisional determination to Pfizer’s COVID-19 bivalent (Comirnaty Bivalent Omicron BA.4/BA.5) booster dose vaccine

16 November 2022 - On 15 November 2022, the TGA granted a provisional determination to Pfizer’s bivalent COVID-19 vaccine candidate: tozinameran ...

Read more →

ATAGI recommendations on use of the Pfizer COVID-19 vaccine for children aged 6 months to 4 years

15 November 2022 - On 29 September 2022, the TGA provisionally approved Comirnaty (Pfizer) COVID-19 vaccine for use in children ...

Read more →

ATAGI recommendations on use of the Pfizer bivalent (Original/Omicron BA.1) COVID-19 vaccine

15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred ...

Read more →

ATAGI update on boosters following COVID-19 meeting on 11 November 2022

15 November 2022 - An update from the Australian Technical Advisory Group on Immunisation (ATAGI) following their meeting on 11 November ...

Read more →

COVID-19 vaccine safety report (3 November 2022)

3 November 2022 - To 30 October 2022, the TGA has received 704 reports which have been assessed as likely to ...

Read more →

Pfizer and BioNTech receive positive CHMP opinion for Omicron BA.4/BA.5 adapted bivalent COVID-19 vaccine booster for children 5 through 11 years of age in European Union

10 November 2022 - Pfizer and BioNTech today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (Comirnaty Original/Omicron ...

Read more →

Sanofi and GSK’s next-generation COVID-19 booster vaccine VidPrevtyn Beta approved by the European Commission

10 November 2022 - First and only next-generation protein-based adjuvanted COVID-19 booster approved in Europe. ...

Read more →

New COVID-19 variant leads to increase in cases

8 November 2022 - A statement from Professor Paul Kelly, Australian Government Chief Medical Officer, on the increase in COVID-19 cases ...

Read more →

Moderna receives Health Canada authorisation for second Omicron targeting bivalent booster

4 November 2022 - mRNA-1273.222 targets BA.4/BA.5 Omicron sub-variants and follows the approval of mRNA-1273.214 (SPIKEVAX Bivalent) in Canada, which ...

Read more →

Health Canada authorises second bivalent COVID-19 booster targeting the Omicron BA.4/5 variants

3 November 2022 - Today, Health Canada authorised an adapted version of the Moderna Spikevax COVID-19 vaccine that targets the Omicron ...

Read more →

Vaxzevria receives full marketing authorisation in the EU for the prevention of COVID-19

1 November 2022 - AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted full marketing authorisation in the European Union. ...

Read more →

Expanded access to COVID-19 oral antiviral treatments on the PBS

1 November 2022 - Expanded eligibility criteria for COVID-19 oral anti-viral treatments (Lagevrio (molnupiravir) and Paxlovid (nirmatrelvir and ritonavir) ...

Read more →

Actemra IV (tocilizumab for injection) receives authorisation for additional indication from Health Canada for the treatment of COVID-19

28 October 2022 - Actemra is shown to improve outcomes including mortality in patients hospitalised with COVID-19 requiring supplemental oxygen. ...

Read more →

TGA provisionally approves Pfizer bivalent COVID-19 vaccine for use as a booster dose in adults

28 October 2022 - On 27 October 2022, the TGA provisionally approved Pfizer’s bivalent COVID-19 vaccine, tozinameran and riltozinameran (COMIRNATY Original/Omicron ...

Read more →

ATAGI recommendations for a booster dose of the paediatric Pfizer COVID-19 vaccine in children aged 5 to 11 years

24 October 2022 - Recommendations from the Australian Technical Advisory Group on Immunisation on Pfizer booster doses for children aged 5 ...

Read more →